New test could predict immunotherapy success from live tumor samples

NCT ID NCT05520099

Ongoing Knowledge-focused Sponsor: Elephas Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whether a patient will respond to immunotherapy. The platform's accuracy will be compared to standard tumor measurements and FDA-approved biomarkers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a test that helps doctors predict which patients will benefit from immunotherapy, improving treatment decisions.
What could go wrong: This is an early-stage observational study, not a treatment trial. The platform may not prove accurate enough in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma cancer clear cell renal carcinoma colorectal cancer colorectal neoplasm cutaneous melanoma endometrial cancer endometrium neoplasm head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma hepatocellular carcinoma kidney cancer liver cancer Liver Neoplasms lung cancer lung neoplasm Lynch syndrome melanoma neoplasm non-small cell lung carcinoma nonpapillary renal cell carcinoma renal cell carcinoma skin cancer skin neoplasm Squamous Cell Carcinoma of Head and Neck urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER CANCER CLEAR CELL RENAL CELL CANCER (CCRCC) COLORECTAL CANCER CUTANEOUS MELANOMA DMMR COLORECTAL CANCER ENDOMETRIAL CANCER HEAD AND NECK CANCER (H&N) HEPATOCELLULAR CARCINOMA (HCC) IMMUNOTHERAPY KIDNEY CANCER LIVER CANCER LUNG CANCER (NSCLC) MSI-H COLORECTAL CANCER NSCLC (NON-SMALL CELL LUNG CANCER) SKIN CANCER SOLID TUMOR CANCER SQUAMOUS CELL CARCINOMA HEAD AND NECK CANCER (HNSCC) UROTHELIAL CARCINOMA BLADDER

Contacts and locations

Locations

AdventHealth Orlando

Orlando, Florida, 32803, United States
CARTI Cancer Center

Little Rock, Arkansas, 72205, United States
Cleveland Clinic Florida

Stuart, Florida, 34994, United States
John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
Memorial Health System

Pembroke Pines, Florida, 33026, United States
Meritus Center for Clinical Research

Hagerstown, Maryland, 21742, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14203, United States
Salinas Valley Memorial Healthcare System

Salinas, California, 93901, United States
University of Louisville James Graham Brown Cancer Center

Louisville, Kentucky, 40202, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States
University of South Florida (Tampa General Hospital)

Tampa, Florida, 33606, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.